| √ | □特定对象调研 □分析师会议 | | --- | --- | | | □媒体采访 □业绩说明会 | | 投资者关系活动 类别 | □新闻发布会 □路演活动 | | | □现场参观 □一对一沟通 | | | □其他（ ） | | 参与单位及人员 | 中信建投证券股份有限公司、银华基金管理股份有限公司分 | | | 析师、研究员 | | 时间 | 2025 年 11 月 24 日 14:30～15:30 | | 地点 | 公司会议室 | | 形式 | 现场交流 | | 上市公司 | 1、公司董事会秘书 杨威 | | 接待人员 | 2、公司证券事务代表 陈子敏 1、公司昂拉地韦片有什么特色，是否对 H3N2 毒株有效？ | | | 答：昂拉地韦片是全球首款 RNA 聚合酶 PB2 靶点的甲型 流感口服药物，具有快速、强效、低耐药的特点，能够快速缓 | | | 解全身流感症状、强效抗击流感病毒，兼具低耐药性。 | | | 临床前研究结果表明，对包括奥司他韦耐药株、高致病性 | | 交流内容及具体 | 禽流感病毒株和巴洛沙韦耐药株等在内的多种不同亚型流感 | | 问答记录 | 病毒株具有强大的抑制活性。昂拉 ...

每经AI快讯，有投资者在投资者互动平台提问：公司的创新药减肥药RA1225，为什么能直接进入美国 FDA二期实验？一期不要做吗？ 众生药业（002317.SZ）11月24日在投资者互动平台表示，公司 RAY1225 注射液可在美国开展超重或肥 胖适应症的II期临床试验，系遵循国际和当地新药审评规范的合规推进。公司于2024年12月向美国食品 药品监督管理局（以下简称"FDA"）递交了RAY1225注射液在中国人群的I期和RAY1225注射液治疗中 国肥胖/超重患者与2型糖尿病患者的II期临床研究当时已获得的安全性和有效性数据，申请在美国开展 超重或肥胖患者的II期临床研究，目前FDA已经完成了RAY1225注射液递交资料的安全性审查，同意 RAY1225注射液直接在美国开展超重或肥胖适应症的II期临床试验。 （文章来源：每日经济新闻） ...

Core Insights - The article highlights significant corporate announcements and developments in various companies, focusing on their strategic moves and market positions. Company Developments - Joyoung Co., Ltd. clarifies that it and its subsidiaries are not involved in the food and beverage sectors, emphasizing its focus on small home appliances [2] - Rongbai Technology is set to become the primary supplier of sodium battery cathode materials for CATL, with a commitment from CATL to purchase no less than 60% of its total procurement from Rongbai [2] - Heshun Petroleum's actual controller and related parties plan to transfer 6% of the company's shares [2] - Fudan Microelectronics reports that Guosheng Investment intends to acquire 12.99% of shares from Fuxin Fangao, making it the largest shareholder [2] - Maihe Co., Ltd.'s controlling shareholder and chairman Wang Jinping is under investigation and has been detained [2] - Furi Co., Ltd. states that its new energy division currently has no plans for expansion [2] Mergers and Acquisitions - Heshun Petroleum is planning a cross-border acquisition of control over Kuixin Technology, which focuses on integrated circuit IP and Chiplet product development [3] - Chuangye Huikang is in the process of planning a change in control, with its stock set to resume trading [4] Shareholding Changes - Qianli Technology's shareholder Jianghehui plans to reduce its stake by up to 2% [4] - China Aluminum's director Jiang Tao intends to sell no more than 57,500 shares [4] - Time Space Technology plans to reduce its repurchased shares by up to 290,700 [4] Contracts and Project Wins - Samsung Medical's subsidiary is expected to win a procurement project from the State Grid worth approximately 168 million yuan [4] Stock Price Movements - Zhongsheng Pharmaceutical's stock is experiencing volatility due to uncertainties in the clinical trial progress and approval results of its innovative drug projects [4] - True Love Home's major shareholder confirms that there are no asset restructuring plans in the next 12 months [5] Other Notable Events - Haosai reports that the local prosecutor's office has appealed a first-instance judgment, leading to uncertainty regarding the final ruling [3] - Guolian Minsheng has received approval for its stock option market-making business [6] - Huaxia Happiness is undergoing pre-restructuring proceedings as accepted by the Langfang Intermediate Court [6] - Zai Jing Pharmaceutical's injectable ZG006 has received orphan drug designation from the FDA for treating neuroendocrine cancer [6]

Group 1 - The company's stock (Zhongsheng Pharmaceutical, stock code: 002317) experienced an abnormal trading fluctuation, with a cumulative closing price increase exceeding 20% over three consecutive trading days from November 12 to November 14, 2025 [2] - The company's board of directors conducted a verification and found no need for corrections or supplements to previously disclosed information, and no significant undisclosed information affecting stock prices was identified [2][3] - The company's current operational situation is normal, with no significant changes in the internal or external business environment [2] Group 2 - The board confirmed that there are no undisclosed matters that should be disclosed according to the Shenzhen Stock Exchange listing rules, nor any related planning or negotiations that could significantly impact the stock price [3] - The company has not violated any information disclosure regulations and will continue to fulfill its disclosure obligations in accordance with relevant laws and regulations [5]

Core Viewpoint - Multiple companies have issued risk warnings regarding their stock performance, indicating potential irrational market speculation and volatility risks due to significant recent price increases [1][4][8]. Group 1: Company Announcements - Pingtan Development announced that its stock price has surged over 220% since October 17, with a market capitalization increase from 6.5 billion to 21 billion [5]. - Gohome China reported a 256.29% cumulative increase in stock price over 14 trading days, with 12 days closing at the daily limit, and highlighted the risk of market sentiment overheating [2][3]. - Suning Pharmaceutical is advancing several clinical trials for innovative drugs, but the outcomes remain uncertain, posing risks to its stock performance [6][7]. Group 2: Market Conditions - Gohome China's static P/E ratio reached 343.67, significantly higher than the industry average of 30.94, indicating a potential valuation bubble [3]. - Several companies, including Dongbai Group and Renmin Tongtai, have also warned of trading risks due to abnormal stock price fluctuations and market sentiment [8][9]. - The Shanghai Stock Exchange has taken regulatory measures against abnormal trading behaviors, monitoring stocks with significant price volatility [3].

Group 1 - On November 14, Zhongsheng Pharmaceutical (002317) experienced a trading halt, closing at 26 CNY per share, with a total market capitalization of 22.1 billion CNY, and a cumulative increase of over 22% in the last three trading days [1][4] - The company announced on November 16 that it is advancing several Phase III clinical trials for its innovative drugs, including Anglavei granules for treating influenza in children aged 2-11 and Anglavei tablets for adolescents aged 12-17, as well as RAY1225 injection for obesity and type 2 diabetes [4][5] - Anglavei tablets are recognized as the world's first oral drug targeting the PB2 site of RNA polymerase for influenza, noted for their rapid, potent, and low-resistance characteristics, with significant recognition from the international academic community [5] Group 2 - The clinical trial progress, review, and approval outcomes for the innovative drug projects carry certain uncertainties, including the potential for drug approval and subsequent market competition dynamics [4] - Other companies, such as Furui Co., Ltd. (002083), have also issued announcements regarding stock price fluctuations, indicating challenges in their respective sectors, particularly in the lithium battery industry [6][7]

Group 1 - Rongbai Technology signed a cooperation agreement with CATL, becoming its primary supplier of sodium battery cathode materials, with a commitment to supply at least 60% of CATL's total procurement volume if annual purchases exceed 500,000 tons [3] - Meihe Co., Ltd.'s controlling shareholder and chairman Wang Jinping is under investigation and has been placed under detention, with the general manager Zhang Kaixu taking over the chairman's responsibilities [4] - Fudan Microelectronics announced that Guosheng Investment plans to acquire 12.99% of its shares from Fuxin Fangao, making Guosheng the largest shareholder post-transfer [5] Group 2 - Guolian Minsheng received approval from the China Securities Regulatory Commission for its stock option market-making business [6] - Luoping Zinc Electric's subsidiary has received approval to resume production at the Jinpo lead-zinc mine, having met safety and operational requirements [7] - Heshun Petroleum's actual controller and associates plan to transfer 6% of the company's shares through an agreement, maintaining control post-transfer [8] Group 3 - Furi Co., Ltd. stated that there are currently no expansion plans for its new energy sector, amid stock price volatility and potential irrational speculation [9] - Joyoung Co., Ltd. clarified that it operates in the small home appliance sector and does not engage in food and beverage product development or sales [10] - Huaxia Happiness reported abnormal stock trading but confirmed no undisclosed significant matters aside from its pre-restructuring announcement [11] Group 4 - Zhongsheng Pharmaceutical is advancing several clinical trials for its innovative drugs, but the outcomes remain uncertain [12] - Pingtan Development noted that its stock price has risen sharply without significant changes in fundamentals, indicating potential market overreaction [13] Group 5 - Chahua Co., Ltd. announced that a major shareholder plans to reduce its stake by up to 3% within three months [14] - Qianli Technology's major shareholder intends to reduce its stake by up to 2% through a private placement [15] - Gaoling Information's shareholders plan to collectively reduce their holdings by up to 1.5% due to funding needs [16] Group 6 - Guochuang High-tech's major shareholder plans to reduce its stake by up to 1% within three months [17] - China Aluminum's director plans to reduce his stake by a minimal amount of 0.00034% due to personal funding needs [18] - Shikong Technology plans to reduce up to 0.29% of its repurchased shares [19] Group 7 - Xinong Co., Ltd.'s vice president plans to reduce his stake by up to 0.1925% due to personal funding needs [20] - Yifeng Pharmacy's vice presidents plan to collectively reduce their holdings by up to 213,900 shares [21] Group 8 - Samsung Medical's subsidiary is expected to win a procurement project from the State Grid, with an estimated total bid amount of approximately 168.12 million yuan [22]

Group 1 - Rongbai Technology signed a cooperation agreement with CATL, making Rongbai the primary supplier of sodium battery cathode powder, with a commitment to purchase at least 60% of its total procurement volume annually, potentially reaching 500,000 tons [3] - Meihe Co.'s controlling shareholder and chairman Wang Jinping is under investigation and has been placed under detention, with the general manager Zhang Kaixu taking over the chairman's responsibilities [4] - Fudan Microelectronics announced that Guosheng Investment plans to acquire 12.99% of its shares from Fuxin Fangao, making Guosheng the largest shareholder post-transfer [5] Group 2 - Guolian Minsheng received approval for stock option market-making business from the China Securities Regulatory Commission [6] - Luoping Zinc Electric's subsidiary has received approval to resume production at the Jinpo lead-zinc mine, having met safety and operational requirements [7] - Heshun Petroleum's actual controller and associates plan to transfer 6% of the company's shares through an agreement, maintaining control post-transfer [8] Group 3 - Furi Co. stated that there are currently no expansion plans for its new energy sector, amid stock price volatility and potential irrational speculation [9] - Joyoung Co. clarified that it operates in the small home appliance sector and does not engage in food and beverage production, despite recent market speculation [10][11] - Huaxia Happiness reported abnormal stock trading but confirmed no undisclosed significant matters aside from its pre-restructuring announcement [12] Group 4 - Zhongsheng Pharmaceutical is advancing several clinical trials for its innovative drugs, but the outcomes remain uncertain, including the approval and market competition for its products [13] - Pingtan Development noted that its stock price has risen sharply without significant changes in fundamentals, indicating potential market overreaction [14] Group 5 - Chahua Co. announced that its major shareholder plans to reduce its stake by up to 3% within three months [16] - Qianli Technology's major shareholder intends to reduce its stake by up to 2% through a targeted sale [17] - Gaoling Information's shareholders plan to collectively reduce their holdings by up to 1.5% due to funding needs [18] Group 6 - Guochuang High-tech's major shareholder plans to reduce its stake by up to 1% within three months [19][20] - China Aluminum's director plans to sell a minimal stake of 0.00034% due to personal funding needs [21] - Shikong Technology plans to reduce its repurchased shares by up to 0.29% [22] Group 7 - Xinong Co.'s director plans to reduce his stake by up to 0.1925% due to personal funding needs [23] - Yifeng Pharmacy's vice presidents plan to collectively reduce their holdings by up to 213,900 shares due to personal funding needs [24] Group 8 - Samsung Medical's subsidiary is expected to win a procurement project from the State Grid, with an estimated total bid amount of approximately 168.12 million yuan [26]

众生药业发布异动公告称，目前，公司正在推进昂拉地韦颗粒治疗2~11岁儿童单纯性甲型流感患者和 昂拉地韦片治疗12~17岁青少年单纯性甲型流感患者的两项III期临床试验、RAY1225注射液治疗肥胖/超 重患者的III期临床试验、以及RAY1225注射液治疗2型糖尿病患者的两项III期临床试验。创新药研发项 目的临床试验进度、审评和审批的结果以及未来产品市场竞争格局都具有一定的不确定性。药品能否获 批上市以及获批上市的时间、上市后的生产和销售情况存在不确定性。此外，用于治疗成人单纯性甲型 流感的小分子创新药昂拉地韦片已获得国家药品监督管理局批准上市，是全球首款流感RNA聚合酶PB2 蛋白抑制剂。未来昂拉地韦片的商业化和销售情况存在不确定性。（第一财经） ...

每经AI快讯，11月16日，众生药业（002317）(002317.SZ)发布股票交易异常波动的公告，目前，公司 正在推进昂拉地韦颗粒治疗2~11岁儿童单纯性甲型流感患者和昂拉地韦片治疗12~17岁青少年单纯性甲 型流感患者的两项III期临床试验、RAY1225注射液治疗肥胖/超重患者的III期临床试验、以及RAY1225 注射液治疗2型糖尿病患者的两项III期临床试验。创新药研发项目的临床试验进度、审评和审批的结果 以及未来产品市场竞争格局都具有一定的不确定性。药品能否获批上市以及获批上市的时间、上市后的 生产和销售情况存在不确定性。此外，用于治疗成人单纯性甲型流感的小分子创新药昂拉地韦片已获得 国家药品监督管理局批准上市，是全球首款流感RNA聚合酶PB2蛋白抑制剂。未来昂拉地韦片的商业化 和销售情况存在不确定性。 ...